Homing of peripherally injected bone marrow cells in rat after experimental myocardial injury by Ciulla, Michelem et al.
614 haematologica/journal of hematology vol. 88(06):june 2003
Background and Objectives. Significant progress has
been achieved during the past 10 years in cell trans-
plantation and recent research has focused on the pos-
sibility of improving ventricular function after myocardial
infarction. Most studies in the field of cardiac tissue repair
are performed by direct intramyocardial injection of cells
of different origin. Since this approach requires a surgi-
cal intervention, in this study we investigated the feasi-
bility of non-invasive administration of bone marrow
mononuclear cells (BMMNCs) by assessing the fate of
peripherally injected, purified, labeled cells in cryodam-
aged hearts.
Design and Methods. Ten donor and ten recipient
inbred isogenic adult (4 weeks old) Fisher rats were used
as models to mimic autologous transplantation. Myocar-
dial damage was obtained in recipient rats by placing a
frozen metal probe on the anterior left ventricular wall for
15 seconds (freeze-thaw injury technique). BMMNCs were
purified and labeled with a red fluorescent cell dye. Sev-
en days after the injury about 15–25×106 cells were
infused through the femoral vein of recipient rats. Seven
days after the infusion, the heart, lungs, liver, kidneys,
spleen and thymus were harvested to track transplanted
cells.
Results. Labeled cells were found only in the injured
area of the heart and not in the normal tissue; a limited
number of cells were also identified in the spleen of all
the animals. Most of the labeled cells in the infarcted
area were Thy-1+ and some were CD34+.
Interpretation and Conclusions. Our data suggest that
peripherally injected BMMNCs can traffic through the cir-
culation to the site of damage; we hypothesize that tis-
sue injury leads to the priming of a cytokine cascade act-
ing as chemoattractant for the infused cells.
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Recently it has been demonstrated that stem cells,particularly those from the bone marrow (BM), havethe capacity to colonize different tissues, prolifer-
ate and transdifferentiate into cell lineages of the host
organ.1,2 In fact, it has been shown that there are pluripo-
tent progenitor cells in the BM which can differentiate
into muscle, cartilage, bone, fat and tendon.3,4 Therefore,
it has been proposed that somatic cell therapy protocols
can be developed to treat a number of diseases, includ-
ing cardiovascular ones. In this regard, several authors
have recently investigated different strategies to renew
myocardium after myocardial infarction, including direct
transplantation of cardiomyocytes or skeletal
myoblasts.5,6 However, so far these approaches have
invariably failed to reconstitute healthy myocardium and
coronary vessels structurally and functionally integrated
with the ventricular wall.7 The injection of BM stromal
cells, containing adult stem cells, into the contracting
myocardium bordering an acute infarct, has been proven
to be feasible,8,9 as shown by the homing and transdif-
ferentiation of these cells into cardiomyocytes. Most
studies in this field were performed by direct injection of
various cells into the myocardium. However, this
approach requires a surgical intervention that may be
associated with significant  morbidity and mortality as
well as with a limited grafting success rate. More recent-
ly the possibility of injecting BM stromal cells directly
into the clamped aorta, with subsequent migration of the
cells through the coronary arteries to the infarction scar,
has been reported.10 In this study we tested the hypoth-
esis that tissue damage acts as a chemoattractant for
stem cells by assessing the fate of peripherally injected,
purified, labeled bone marrow mononuclear stem cells
(BMMNCs) in rats with artificially injured cardiac muscle.
Design and Methods
Animals
In order to mimic autologous infusion of BMMNCs for
future clinical application, we used an animal model,  car-
rying out our experiments in 23 male adult inbred Fish-
er rats (Charles River Laboratories, Italy), weighing 200-
250 g. Animals were housed and handled in accordance
with the Guide for the Care and Use of Laboratory Animals
prepared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the Nation-
al Academy Press (1996 revision) and the Guide for the
Care and Use of Experimental Animals of the Canadian
Council on Animal Care.
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Experimental injury
Cardiac injury was induced using the freeze-
thaw technique in 13 recipient rats (10 subse-
quently treated animals and 3 controls). This tech-
nique, previously described in a model of myoblast
transplantation for the repair of myocardial necro-
sis,5 consists in positioning a precooled (liquid
nitrogen, -190°C) aluminum rod (9 mm diameter)
at the target location. The resulting injury is then
produced by creating a negative thermic gradient
from the tissue to the contiguous precooled instru-
ment. In our study, the animals were placed under
diethyl ether anesthesia and spontaneous respira-
tion in the right lateral decubitus position. After
immobilization, they underwent depilation and dis-
infection of the left thorax. The heart was then
rapidly exposed aseptically via a left thoracotomy
through the third or the fourth intercostal space;
the myocardial damage was produced by placing
the probe in direct contact with the anterior left
ventricular wall for 15 sec (Figure 1). The exact
position of the instrument was carefully fixed by
using the right auricular appendage and the origin
of the pulmonary trunk as anatomical landmarks.
The cryodamaged area was macroscopically iden-
tified as a firm, white disk-shaped region of coag-
ulation necrosis. After the injury, the heart was
rapidly repositioned within the thoracic cavity and
the chest closed with 5-0 vicryl sutures.
Echocardiography
The myocardial lesion was assessed in the acute
setting (24 hours after the injury) by transthoracic
echocardiography. The rats were examined, with
the chest closed, under diethyl ether anesthesia, in
the left lateral decubitus position, using an
echocardiographic system (Kontron Sigma 44 HVD,
Les Gatines, France) equipped with a 7.5 MHz
mechanical probe (focus depth set at 3.0 cm, sec-
torial angle of 60°). In order to identify the phase
of the cardiac cycle, 3 electrodes were attached to
the animal’s paws to obtain a simultaneous elec-
trocardiographic tracing. Infarct size was estimat-
ed at end diastole from the short-axis echoes by
observing the akinetic region in real time and mea-
suring (planimetry) the percentage of the endo-
cardial circumference of the left ventricle, which
was hypo- or hyperechogenic, compared with the
non-infarcted region.
Isolation of BMMNCs
Isolation of BMMNCs from the femoral and tib-
ial bones of donor rats (n=10) was performed using
a previously described method.11 After an overdose
of sodium pentobarbital (100 mg/kg, i.p.) the femo-
ra and tibiae were collected. Both ends of the bones
were cut away from the diaphyses, the marrow
cavities were flushed with Dulbecco’s modified
Eagle’s medium (DMEM, Sigma, St. Louis, MO, USA)
including 0.02M ethylenediaminetetraacetic acid
(EDTA, Sigma, St. Louis, MO, USA) and 5% fetal
bovine serum (FBS; GIBCO, BRL Grand Island, NY,
USA). The collected cells were transferred into a
sterile tube containing 50 mL of culture medium
(DMEM + 5% FBS + 10% EDTA). After two wash-
es, the pellet was resuspended in 5 mL of culture
medium. Mononuclear cells were isolated by den-
sity gradient centrifugation through Lympholyte-H
(1.077 g/mL; Cedarlane, Hornby, Ontario, Canada)
at 400 g for 30 min at room temperature and the
interface cells were collected and washed twice in
Ca2+-Mg2+- free Dulbecco’s phosphate-buffered
saline (PBS; GIBCO BRL Grand Island, NY, USA) con-
taining 1% bovine serum albumin (BSA; Sigma, St.
Louis, MO, USA).
Labeling of BMMNCs
The cells were centrifuged at 400 g for 10 min
using a medium without serum. The PKH26 dye
(Sigma), a red fluorescent cell linker (4×10-6 M) was
added and the cell suspension was incubated for 5
min at 25°C inverting the tube periodically. Then an
equal volume of serum was added and the sus-
pension was incubated for 1 min. After this incu-
bation the sample was centrifuged twice at 400 g
for 10 min at 25°C to remove cells from the stain-
ing solution and the pellet was resuspended in
DMEM at a concentration of about 20×106 cells in
500 µL for transplantation. The stained sample was
examined with flow cytometry to evaluate the flu-
orescence intensity and the percentage of marked
cells. The purity of the labeled BMMNCs was eval-
uated by flow cytometric analysis before trans-
plantation.
Seven days after transplantation, the percentage
of labeled BMMNCs was evaluated in the BM of
the rats by flow cytometric analysis.
Cell injections
Seven days after the injury, the recipient rats
were prepared for the infusion of BMMNCs. The
rats were anesthetized (ketamine, 2 g/Kg body
weight  i.p.) and the femoral vein surgically isolat-
ed and exposed. The BMMNC suspension (500 µL)
containing a median of 20 (17-28) ×106 cells was
infused using a tuberculin sterile syringe with a
23G needle. The wound was then closed with 5-0
vicryl sutures. The control rats were injected with
normal saline (500 µL).
Pathology examination and histologic
staining 
Seven days after the BMMNC injection (2 weeks
after the experimental injury), the rats were sacri-
ficed with an overdose of sodium pentobarbital.
The heart was exposed through a sternotomy,
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arrested in diastole with an injection of potassium
chloride (10 mEq) and the site of myocardial injury
was identified. In each rat, transverse sections
about 5 mm in thickness were made across the
major axis of the liver, lung, kidney, thymus and
spleen. Two transverse sections of infarcted
myocardium and one of not-infarcted myocardium
of about 3-5 mm in thickness were taken from the
ventricular cavities. From each frozen block, 10 sec-
tions (5 µm in thickness) at 50 µm intervals were
cut. Of every 10 sections, 1 was stained with hema-
toxylin and eosin, 4 were air-dried for 2 hours at
room temperature in darkness and then mounted
with a permanent aqueous mounting medium
(Supermount, Biogenex, San Ramon, CA, USA) and
5 were stored for immunofluorescence and
immunohistochemistry analysis.
To exclude the migration of labeled BMMNCs to
their site of origin, the BM of all recipients was
also harvested.
Estimates of the cells homing to tissues
Fluorescence was revealed with a reflected light
fluorescence microscope (Olympus BX 60, Ham-
burg, Germany) at 1000X using a rhodamine filter
(Olympus BP510-550). The homing of BMMNCs
was estimated in each tissue by counting the num-
ber of red fluorescent cells in each section exam-
ined.
Identification of the injected population
Immunofluorescence and immunohistochemistry
analyses were performed on the frozen sections of
infarcted and non-infarcted myocardium in order
to assess the Thy-1 FITC (clone OX-7; Becton Dick-
inson, San Jose, California, USA) and CD34 (clone
ICO115; Santa Cruz Biotechnology Inc., Santa Cruz,
California, USA) positive mononucleated cells,
respectively. In order to visualize the heart tissue in
the background when showing PKH26+ cells, an
indirect immunofluorescence stain was applied,
using sarcomeric actin (clone α-Sr-1; DAKO,
Glostrup, Denmark). The frozen sections were fixed
with cool acetone (4°C) for 5 min, washed in PBS
(pH 7.4, 0.1 M) and stained with specific antibod-
ies. The antibodies were applied for 1 hour at a
working dilution of 1:10 for Thy-1, 1:50 for CD34
and 1:20 for sarcomeric actin. Immunofluorescent-
positive cells were identified using a reflected light
fluorescence microscope (Olympus BX 60) at 1000X
connected to a CCD camera (COHU 2200, Cohu
Inc., San Diego, CA, USA). Images were post-
processed by computer image analysis software
(MacProbe v. 4.1, Perceptive Scientific Instruments
Inc., League City, TX, USA). Diaminobenzidine (DAB)
was used as the chromogen for CD34 immunos-
taining.
Statistics
Data were analyzed using computer statistical
software (SPSS - Rel 6.1.1; SPSS Inc., Chicago, Illi-
nois, USA). Infarcted areas are reported as mean ±
standard deviation. The reproducibility of the
experimental injury in all studied animals is report-
ed as the coefficient of variation (CV) of the sizes
of the infarcts obtained in the acute setting (24
hours after the freeze-thaw injury), as evaluated by
echocardiography. Correlation between echo-
graphic and histologic estimates of infarcted areas
was evaluated by linear regression analysis. A p
value less than 0.05 is considered statistically sig-
nificant.
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Figure 1. Left panel: 2D short axis
echocardiographic images obtained
in one of the studied animals at end
diastole (upper panel) and at end sys-
tole (lower panel) showing the size of
the injury (white arrows). Echocar-
diograms were performed in the acute
setting (24 hours after the injury)
with a 7.5 MHz mechanical probe; the
focus depth and the sectorial angle
were set at 3.0 cm and 60°, respec-
tively. Right panel: Microscopic
image (hematoxylin-eosin, 40×)
showing freeze-thaw injuries. At the
bottom and the lower-right corner of
the figure the necrotic area with a
dense lympho-granulocyte infiltrate
can be identified. In the upper-left cor-
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On echocardiograms performed 24 hours after the
injury, the left anterior myocardial wall of the rats
showed akinetic and echodense areas that were con-
sidered as infarcted areas (Figure 1); the measured
mean area of infarction in all studied animals was
21.2±3.4% of the transverse left ventricular free
wall, with a CV of 0.16. Gross examination of the
excised hearts at the end of the study (14 days after
injury) showed clear myocardial scar formation; the
histologic examination, conducted at the same lev-
el as the echocardiograms, confirmed the presence
of a regular non-transmural scar of about
18.5±3.2% of the entire left ventricular free wall.
Estimates of infarcted myocardium by echocardiog-
raphy were in agreement with those obtained by his-
tology (r = 0.70, p = 0.02). Ischemic infarcts usually
have irregular borders with viable peninsulas of
subepicardial myocardium along penetrating vessels,
whereas freeze-thaw injuries consist of confluent
necrosis in the subepicardium, with viable myocardi-
um in the subendocardium (Figure 1). Despite these
differences, the cellular patterns of coagulation
necrosis, inflammation and phagocytosis, granula-
tion tissue formation and scarring after freeze-thaw
injury are indistinguishable from ischemic myocar-
dial infarction, making it a suitable model to study
myocardial repair.12-14
Labeling and fate of injected BMMNCs
The median percentage of the PKH26-labeled
BMMNCs before injection was 84% (range 70-91%)
by flow cytometric analysis.
Figure 2. Panel a: double-fluorescence microscopy image showing sarcomeric actin(+), myocardiocytes (green fluorescence:*)
and PKH26(+) cells (red fluorescence: arrows) within the site of the injury of the left ventricular wall (magnification 1000×).
Panel b: double-fluorescence microscopy image showing PKH26 and CD34 co-expression (red-green fluorescence) in the inject-
ed BMMNCs (arrows), identified in the infarcted area. The asterisk indicates endothelial CD34+ cells used as an internal pos-
itive control (magnification 1000×). Panels b.1, b.2: single fluorescence images obtained from the same field as illustrated in
panel b, showing PKH26+ (red fluorescence) and CD34+ (green fluorescence) cells (magnification 1000×). Panels c.1, c.2: sin-
gle fluorescence images obtained from the same field as illustrated in panel c, showing PKH26+ (red fluorescence) and Thy-1+
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One week after the injection, BMMNCs red flu-
orescent cells were found only in the injured
myocardium (Figure 2A), where 68.75% of the
examined sections each contained a median of 8
(range 5-15) fluorescent cells and in the spleen,
where a smaller number of fluorescent cells were
found (median 3, range 1-3) in 62.5% of the exam-
ined sections. No red fluorescent cells were found
in examined sections from any other target organs
(Table 1). No fluorescence was found in negative
controls. The median percentage of the labeled
BMMNCs detected in the BM after transplantation
was 0.8% (range 0.5-1.5%).
Identification of injected population
One week following the peripheral injection,
PKH26+ cells were found in infarcted areas (Figure
2A). Co-localization of PKH26 and CD34/Thy-1
demonstrated that hematopoietic progenitor cells
had migrated to the injured heart via the periph-
eral circulation and localized just into infarcted
areas (Figure 2B,C). The Thy-1+ cells were homo-
geneously distributed in the infarcted areas with a
decreasing epi-endocardial gradient superimpos-
ing the pattern of injury. The CD34+ cells were iden-
tified close to the viable myocardium bordering the
infarct zone (Figure 3). Positive cells were not iden-
tified outside the infarcted areas or in control rats.
Discussion
It is generally believed that the proliferative
capacity of the adult mammalian myocardium is
limited. Even though evidence exists for adult
myocyte regeneration,15 this concept remains high-
ly controversial. Consequently, cardiomyocyte loss
resulting from injury or disease is essentially irre-
versible. Cell therapy could, therefore, be a new
approach to repair damaged tissue after myocar-
dial infarction.
The cells to transplant and the source of the cells
to isolate are important considerations.
During recent years, a number of in vitro and in
vivo studies reported that BM contains pluripotent
progenitor cells, capable not only of colonizing dif-
ferent tissues, but also of proliferating and trans-
differentiating into cell lineages of host organs
including osteocytes, chondrocytes, adipocytes,
myocytes and even cardiomyocytes.1,3,4,16-18
Although the physiologic significance of such
non-hematopoietic stem cells remains unknown,
these pieces of evidence suggest that pluripotent
stem cells may be used in adults as a way to recov-
er lost functions of damaged tissues, with great
advantages over embryonic stem cells. In fact,
embryonic stem cells raise important ethical and
safety issues regarding their teratogenic potential,
whereas adult stem cells can be easily and safely
used, particularly in an autologous setting.
Recently, it was demonstrated that intravenous-
ly injected bone marrow cells can home to dam-
aged muscle of recipient mice and grow into new
muscle fibers.19-21 These results could have impor-
tant consequences in view of the clinical use of
BM cells in muscular dystrophy and in degenera-
Table 1. Fate of transplanted bone marrow mononuclear cells
(BMMNCs).
Target organ N. of sections % of sections N. of sections % of sections
examined with fluorescent examined with fluorescent
Treated (n = 10) BMMNCs Controls (n = 3) BMMNCs  
Heart 120 45.83 36 0
Infarcted area 80 68.75 24 0
Non-infarcted area 40 0 12 0
Spleen 40 62.5 12 0
Liver 40 0 12 0
Kidney 40 0 12 0
Lung 40 0 12 0
Thymus 40 0 12 0
Total n. of sections 320 25 96 0
Figure 3. Microscopic images showing CD34 immunoreac-
tivity. Non-infarcted area, left panels; infarcted area, right
panels. Lower panels depict a higher magnification of a
detail taken from the upper panels. CD34 brown immunore-
active mononuclear cells are evident only in the infarcted
area. At 40x, some of them can be seen to be in contact
with a vessel (arrows); the asterisk indicates a  small clus-
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tive cardiovascular diseases. Beltrami et al.15 and
Orlic et al.22 showed that BM-derived stem cells,
injected into the border of a myocardial infarct,
homed to the infarcted zone and did not move into
the remaining non-affected portion of the ventric-
ular wall. A large number of stem cells seems to be
required for the migration, multiplication and dif-
ferentiation of these cells into the cell lineage of
the damaged heart or other organs. In fact, the same
authors demonstrated the presence of a subpopu-
lation of myocytes that were not terminally differ-
entiated in adult hearts. These myocytes re-entered
the cell cycle and underwent nuclear mitotic divi-
sion early after infarction. These data opened new
therapeutic possibilities for patients affected by
myocardial infarction (MI). In this regard, Strauer et
al.23 recently demonstrated that autologous BMM-
NCs can be safely administered through the coro-
nary artery to patients 3 days after transmural MI.
They treated 10 patients with standard pharmaco-
logic treatment and additional cell therapy, obtain-
ing a significant reduction in the extension of the
infarct region (evaluated by ventriculography) and
an improvement in cardiac function and contractil-
ity (evaluated by echocardiography) as compared to
the corresponding results in the controls. This was
the first clinical evidence of the safety and efficacy
of BMMNCs in the treatment of MI and the results
obtained by this group are very promising, although
additional information about the cell subsets
involved in myocardial repair must be collected in
order to design more specific cell therapy protocols
and to improve their efficacy.
One relevant issue is the origin of cycling
myocytes in normal and diseased hearts. These pro-
liferating cells could derive from resident car-
diomyocytes or from circulating stem cells that
reach the spared myocardium. However, in the
absence of stimulation by several cytokines, the
number of circulating stem cells is very low. The
repair of the necrotic myocardium may involve
interventions that promote the migration of
endogenous, exogenous, or both types of stem cells
to the infarcted region. Myocyte proliferation may
be a component of the growth reserve of the human
heart, involved in the mechanism through which the
damaged myocardium could be repaired.
The presence of cell division in the non-diseased
part of the heart suggests a continuous turnover of
cells during the life span of the organism. Moreover,
it can be argued that migration of myogenic pre-
cursors from extracardiac sites also occurs at low
level in pathologic conditions such as myocardial
infarction. This hypothesis is supported by recent
studies demonstrating the presence of the Y chro-
mosome in cardiomyocytes of human female allo-
graft hearts transplanted into male patients.24
Furthermore, studies have demonstrated that
mobilization of BM cells into the circulation and,
presumably, their translocation to the infarcted
portion of the heart can be obtained after granu-
locyte colony-stimulating factor (G-CSF) adminis-
tration, leading to a significant magnitude of myo-
cardial repair.8
Different administration routes have been pro-
posed for cell delivery to the damaged myocardi-
um, including intramyocardial25 and intracoronary
injection,10 while few reports exist on intravenous
injection of the cells.26,27
The approach of injecting cells through the cir-
culation was used by Bittira and co-workers.26 They
focused their attention on the homing and short-
term differentiation of mesenchymal stem cells
(MSCs) in the heart, providing no information
about migration to other target organs. Kawamo-
to and co-workers demonstrated that expanded
endothelial progenitors derived ex vivo from human
blood can be efficaciously injected intravenously
into athymic nude rats. They also showed that the
injected cells are capable of integrating and com-
pleting their differentiation in sites of neovascu-
larization in the infarcted area.27 In this study we
demonstrated the feasibility of peripheral injection
of a suspension of BMMNCs, containing adult stem
cells from isogenic rat donors, into recipient rats
with myocardial injury. Our results, which were
obtained following a minimally invasive adminis-
tration route, could have a positive impact on the
development of therapeutic protocols.
To demonstrate the capability of the peripheral-
ly injected BMMNCs to migrate through the circu-
lation to the site of damage, we set up a rat cry-
onecrosis model. This model has advantages and
disadvantages compared with an alternative mod-
el based on the temporary ligation of the coronary
artery. Although the latter more closely reproduces
the pathologic events occurring immediately
before and early after MI, in our opinion the cry-
onecrosis model has the advantage of providing a
homogenous non-transmural scar in a defined
location and of a reproducible size, which facili-
tates the association of the transplanted cells with
the infarcted versus the non-infarcted areas.
To explain our data, we hypothesize that tissue
injury leads to the priming of a cytokine cascade
that acts as a chemoattractant for the infused cells.
The specificity of this effect was confirmed by
examining other possible target organs, including
the lungs, liver, kidneys, spleen and thymus. No
donor BMMNCs were found in any of these possi-
ble targets, except a small number in the spleen
and the BM where, as expected from the
hematopoietic origin of BMMNCs, some were
found. In order to identify the cell population that
migrates to the damaged myocardium, we stained
the sections of infarcted and non-infarcted areas
in both treated rats and controls with two markers
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CD34. The positivity for Thy-1 and CD34 antigens
was observed just in the infarcted region, close to
the viable myocardium. Therefore, we hypothesize
that, 7 days after the injection, this population of
cells had migrated to the scar tissue from unin-
jured myocardium bordering the infarcted zone.
Despite these encouraging findings, much remains
to be determined regarding the role played by
chemoattractant factors and the interactions with
the surrounding microenvironment. In fact, further
studies, in vivo and in vitro, will be addressed to
assessing which cytokines are responsible for the
chemotaxis of the myogenic precursors and
whether these cells are able to generate function-
al tissue capable of performing a cardiac-like duty
cycle and adapting to the complex fiber geometry
of the heart. Moreover, since the feasibility of our
method of injection has been demonstrated, the
goal of our further studies will be to identify the
cells capable of regenerating damaged myocardi-
um by comparing different BMMNC subsets.
In conclusion, our findings suggest that periph-
erally injected BMMNCs can traffic through the
circulation to the site of tissue damage. This fact
simplifies the strategy for cell implantation and
supports the hypothesis that tissue damage, via the
cytokine system, produces a chemotactic gradient
that is sensed by circulating BMMNCs.
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